Janux Therapeutics, Inc. (NASDAQ:JANX) Receives $59.60 Consensus PT from Analysts

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) have received an average rating of “Buy” from the seven research firms that are currently covering the firm, MarketBeat.com reports. Seven research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokers that have covered the stock in the last year is $61.33.

A number of analysts have issued reports on the company. BTIG Research initiated coverage on Janux Therapeutics in a research note on Thursday, March 21st. They issued a “buy” rating and a $62.00 price target on the stock. William Blair restated an “outperform” rating on shares of Janux Therapeutics in a report on Tuesday, February 27th. Jonestrading started coverage on shares of Janux Therapeutics in a research note on Tuesday. They set a “buy” rating and a $70.00 price target on the stock. Wedbush reissued an “outperform” rating and set a $53.00 price objective on shares of Janux Therapeutics in a research note on Monday, March 11th. Finally, Bank of America upped their price objective on Janux Therapeutics from $24.00 to $48.00 and gave the stock a “buy” rating in a report on Wednesday, March 13th.

Institutional Investors Weigh In On Janux Therapeutics

Several institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. raised its stake in shares of Janux Therapeutics by 3.9% in the 4th quarter. Vanguard Group Inc. now owns 979,483 shares of the company’s stock valued at $10,510,000 after acquiring an additional 37,202 shares during the period. Goldman Sachs Group Inc. increased its holdings in Janux Therapeutics by 174.7% in the 4th quarter. Goldman Sachs Group Inc. now owns 39,948 shares of the company’s stock valued at $429,000 after purchasing an additional 25,404 shares in the last quarter. Barclays PLC raised its position in Janux Therapeutics by 166.3% in the fourth quarter. Barclays PLC now owns 47,722 shares of the company’s stock valued at $511,000 after purchasing an additional 29,800 shares during the period. Nuveen Asset Management LLC lifted its stake in shares of Janux Therapeutics by 22.3% during the fourth quarter. Nuveen Asset Management LLC now owns 81,574 shares of the company’s stock worth $875,000 after purchasing an additional 14,872 shares in the last quarter. Finally, Northern Trust Corp boosted its position in shares of Janux Therapeutics by 5.9% in the fourth quarter. Northern Trust Corp now owns 204,002 shares of the company’s stock worth $2,189,000 after buying an additional 11,317 shares during the period. 75.39% of the stock is currently owned by hedge funds and other institutional investors.

Janux Therapeutics Stock Performance

Shares of JANX opened at $48.69 on Monday. Janux Therapeutics has a 1 year low of $5.65 and a 1 year high of $58.69. The company’s 50 day simple moving average is $35.20 and its 200 day simple moving average is $18.09. The company has a market capitalization of $2.52 billion, a price-to-earnings ratio of -36.34 and a beta of 4.18.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings results on Friday, March 8th. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.12. Janux Therapeutics had a negative return on equity of 17.88% and a negative net margin of 721.18%. The company had revenue of $2.46 million for the quarter, compared to analyst estimates of $0.98 million. Equities analysts expect that Janux Therapeutics will post -1.41 EPS for the current fiscal year.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.